



SEIZURE

Effective: January 1, 2021
Replaces: January 1, 2020
Review: January 1, 2023

1. BLS Treatment

- 1.1. Routine Medical Care – Adult (**700-S04**)
 - 1.1.1. **Oxygen** – titrate as appropriate
- 1.2. Protect patient during active seizure.
- 1.3. Spinal Motion Restriction as appropriate (**700-M11**).
- 1.4. Recovery position with head elevated, if no suspected spinal injury or mechanism
- 1.5. Consider cooling measures if febrile (loosen blankets and/or remove excessive clothing)
- 1.6. **Blood Glucose Level** (BGL), if less than 80mg/dl, treat for hypoglycemia (**700-A03**)

2. ALS Treatment (for active seizure and/or status epilepticus)

- 2.1. Active Seizure without Vascular Access:
 - 2.1.1. **Midazolam 10 mg IM**
 - 2.1.2. After IM midazolam establish **Vascular Access (IV)**, TKO
 - 2.1.3. If unable to establish IV access and patient has continued seizure, **Midazolam 5 mg IM**; not to exceed a total dose of 15 mg
- 2.2. Active Seizure with Vascular Access (IV):
 - 2.2.1. **Midazolam 2.5 mg IV** (slowly titrated to effect in increments of no more than 2.5mg); not to exceed a total dose of 15 mg
- 2.3. Post Seizure:
 - 2.3.1. **Vascular Access (IV)**, TKO
 - 2.3.2. If patient has a recurrent seizure **Midazolam 2.5 mg IV** (slowly titrated to effect in increments of no more than 2.5 mg; not to exceed a total dose of 15 mg)
- 2.4. **BASE CONTACT**: if additional Midazolam above 15 mg total is needed